CYTOKINETICS INC (CYTK)       45.01  +0.45 (+1.01%)

45.01  +0.45 (+1.01%)

US23282W6057 - Common Stock - After market: 45.01 0 (0%)


Fundamental Rating

3

Overall CYTK gets a fundamental rating of 3 out of 10. We evaluated CYTK against 641 industry peers in the Biotechnology industry. CYTK scores bad on very profitability, while its financial health is fine. Not spectacular, but in line with the averages. CYTK shows excellent growth, but is valued quite expensive already.

Note: CYTK has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

The Piotroski-F score of CYTK is 3.00. This is a low score and indicates issues in the health and profitability of CYTK.

VS Industry

Valuation

Valuation Rating

0

CYTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year CYTK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Growth

Growth Rating

7

CYTK is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 22.37% yearly.
CYTK shows a strong growth in Revenue. In the last year, the Revenue has grown by 587.85%.
CYTK is expected to show a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 98.44% yearly.

The Revenue growth is accelerating: in the next 5 years the growth will be better than in the last years.
The earnings per share for CYTK have decreased by -1.29% in the last year.
Measured over the past 5 years, CYTK shows a decrease in Revenue. The Revenue has been decreasing by -7.92% on average per year.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -1.29% -46.78% -28.75% -12.77% 22.37%
Revenue-7.92% 30.76% 587.85% 367.47% 66.08% 86.06% 98.44%

Health

Health Rating

5

A Current Ratio of 11.56 indicates that CYTK has no problem at all paying its short term obligations.
The Current Ratio of CYTK is much better than the industry average of 6.18.
CYTK has a Quick Ratio of 11.56. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.
CYTK is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 6.05.

CYTK has a Altman-Z score comparable to the industry average, which is at -0.10.
CYTK has an Altman-Z score of 0.82. This is a bad value and indicates that CYTK is not financially healthy and even has some risk of bankruptcy.
CYTK has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of CYTK.
VS Industry

Quick Ratio (11.56) VS Industry: 75% outperformed.

0.04
84.53

Current Ratio (11.56) VS Industry: 75% outperformed.

0.08
85.09

Altman-Z (0.82) VS Industry: 55% outperformed.

-2,801.75
658.20

Dividend

Dividend Rating

0

CYTK does not give a dividend.

CYTOKINETICS INC45.01

NASDAQ:CYTK (2/3/2023, 7:00:01 PM)+0.45 (+1.01%)

After market: 45.01 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-03 2022-11-03/amc Earnings (Next) 02-22 2023-02-22/amc
Inst Owners 109.74% Inst Owner Change -0.15%
Ins Owners 1.11% Ins Owner Change -1.08%
Market Cap 4.26B Analysts 82.86
Price Target 63.31 (40.66%)

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) 25.28%
Min EPS beat(2) -27.35% Max EPS beat(2) 77.91%
EPS beat(4) 2 Avg EPS beat(4) 25.65%
Min EPS beat(4) -27.35% Max EPS beat(4) 77.91%
Revenue beat(2) 1 Avg Revenue beat(2) 1142.65%
Min Revenue beat(2) -16.64% Max Revenue beat(2) 2301.94%
Revenue beat(4) 2 Avg Revenue beat(4) 747.06%
Min Revenue beat(4) -76.69% Max Revenue beat(4) 2301.94%
PT rev (1m) -0.21% PT rev (3m) -8.84%
EPS NQ rev (1m) 0% EPS NQ rev (3m) -5.84%
EPS NY rev (1m) 0% EPS NY rev (3m) -14.09%
Revenue NQ rev (1m) 0% Revenue NQ rev (3m) -10.47%
Revenue NY rev (1m) 0% Revenue NY rev (3m) -2.13%

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 28.73
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM) -3.13 EY N/A
EPS(NY) -4.69 Fwd EY N/A
FCF(TTM) -2.87 FCFY N/A
OCF(TTM) -2.6 OCFY N/A
SpS 1.57 BVpS -0.17
TBVpS -0.17 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM N/A
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y N/A GM growth 5Y N/A
F-Score 3 Asset Turnover 0.14

Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 529.33%
Profit Quality N/A
Current Ratio 11.56
Quick Ratio 11.56
Altman-Z 0.82
F-Score 3 WACC 9.05%
ROIC/WACC N/A Cap/Depr(3y) 984.73%
Cap/Depr(5y) 635.2% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y -1.29% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q -60%
EPS Next Y -46.78% EPS Next 2Y -28.75%
EPS Next 3Y -12.77% EPS Next 5Y 22.37%
Revenue growth 1Y 587.85% Revenue growth 3Y 30.76%
Revenue growth 5Y -7.92% Revenue growth Q2Q -53.74%
Revenue Next Year 367.47% Revenue Next 2Y 66.08%
Revenue Next 3Y 86.06% Revenue Next 5Y 98.44%
EBIT growth 1Y -8.88% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year -35.29%
EBIT Next 3Y -21.85% EBIT Next 5Y 10.43%
FCF growth 1Y -299.45% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -295.15%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA